Hmmm … how about giving the Pharma partner first dibs on bidding for the unexercised bonus options. They should still pay market price based on Black & Scholes options pricing the full value of the piggies. This will sure to give the market the eternal validation that is missing.
@RaceOncology - Awesome announcement today after the awesome presentation yesterday. I definitely sense RAC is primed for a pitch to new Institutional Investors.
The great news for those still accumulating is that sp reaction is still muted (IMO). Maybe due to tax loss selling and bonus options selling.
Ann: Bisantrene with Decitabine Enhances Cancer Cell Killing, page-57
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
0.000(0.00%) |
Mkt cap ! $267.5M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.57 | $1.53 | $54.85K | 35.68K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1102 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.54 | 2334 | 2 |
View Market Depth
| Last trade - 13.40pm 17/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |